Endovascular treatment of retrograde type A aortic dissection: a decade of experience in a single-center
Clicks: 1
ID: 309951
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #486 of 490 articles by views in Frontiers in surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 490 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ObjectiveThis study aims to evaluate the long-term outcomes of thoracic endovascular aortic repair (TEVAR) in patients with acute or subacute retrograde type A aortic dissection (RTAD). Additionally, it sought to identify the appropriate intraoperative stent landing zone and the optimal stent size.MethodA retrospective analysis was conducted on patients with acute/subacute RTAD who received TEVAR treatment at our hospital from January 1, 2013, to December 31, 2023. The aortic diameter was measured using the IFINIT imaging computing platform. Patient characteristics, surgical details, hospitalization, follow-up data, and aortic remodeling were analyzed. The stent landing zone and stent size were determined based on preoperative computed tomography angiography (CTA) images and intraoperative digital subtraction angiography (DSA), and were further verified through aortic remodeling results.OutcomesA total of 78 patients were included, all of whom were admitted during the acute or subacute phase. In-hospital mortality and 30-day mortality rates were both 6.4%. The 30-day complication rate was 11.5%. The overall technical success rate was 98.7%. With a median follow-up time of 41 months (interquartile range 25.5–71.5 months), the overall cumulative survival rate were 91.7% (95% CI: 85.2%–98.2%) at 1 and 3 years, and 89.3% (95% CI: 81.5%–97.1%) at 5 years. One of the 78 patients developed an isolated ascending aorta dissection 6 months after surgery; this patient remains alive without treatment. During follow-up, positive ascending aortic remodeling was observed in 89.7% of patients.ConclusionTEVAR appears to be a safe, effective, and durable treatment option for carefully selected patients with acute or subacute RTAD. Simultaneously, thorough screening is essential for patients presenting with dissection in the acute phase.
| Reference Key |
imported_1768907608_696f635867f17
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Shu, Xiaojun |
| Journal | Frontiers in surgery |
| Year | 2026 |
| DOI |
10.3389/fcvm.2026.1744586
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.